Atrial Fibrillation clinical trials at UCSF

7 in progress, 3 open to eligible people

Atrial fibrillation is a condition where the heart has an irregular beat. UCSF is comparing apixaban and aspirin to see which is better at preventing strokes in people who survived brain bleeds. They are also researching if avoiding coffee can help with atrial fibrillation. Another trial focuses on improving ablation treatments.

Showing trials for

  • Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

    open to eligible people ages 18 years and up

    Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.

    San Francisco, California and other locations

  • Does Eliminating Coffee Avoid Fibrillation?

    open to eligible people ages 21 years and up

    Given both the increasing population impact of atrial fibrillation (AF) and the widespread consumption of coffee in society, determining an associated benefit or risk of coffee consumption on AF is of great clinical relevance. This pilot study will evaluate the effect of randomly assigning participants undergoing electrical cardioversion to coffee abstinence or coffee consumption over a 6 month period. This pilot study will provide the first, randomized evaluation of coffee on AF outcomes and will provide important information on whether or not coffee has any effect on AF recurrence.

    San Francisco, California

  • Volunteers to Investigate Best Results for Ablation and Novel Therapies for Atrial Fibrillation

    open to eligible people ages 18 years and up

    VIBRANT-AF seeks to: - Identify clinically relevant predictors of effectiveness and complications of AF ablation procedures in a prospective, US-based, multi-center, real-world longitudinal study - Assess changes in modifiable lifestyle-related exposures influence the effectiveness of AF ablation - Determine incidence and predictors of complications of AF ablation procedures Participants will connect with the Eureka Research Platform and answer a series of surveys and activities over a one-year period. They will be asked about lifestyle habits, recurrence of AFib, hospitalizations, and general feelings and emotions.

    San Francisco, California

  • Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects with Persistent Atrial Fibrillation

    Sorry, in progress, not accepting new patients

    The objective of the ADVANTAGE AF Study is to establish the safety and effectiveness of the FARAPULSE Pulsed Field Ablation System (FARAPULSE PFA System) for treatment of drug resistant, symptomatic persistent atrial fibrillation (PersAF).

    San Francisco, California and other locations

  • FARAPULSE ADVENT PIVOTAL Trial PFA System vs SOC Ablation for Paroxysmal Atrial Fibrillation

    Sorry, in progress, not accepting new patients

    This is a prospective, adaptive, multi-center, randomized safety and effectiveness pivotal study comparing the FARAPULSE Pulsed Field Ablation System with standard of care ablation with force-sensing RF catheters and cryoballoon catheters indicated for the treatment of PAF.

    San Francisco, California and other locations

  • ADVENT Trial Long Term Outcomes Evaluating Atrial Fibrillation Progression Study

    Sorry, not yet accepting patients

    The (ADVENT LTO) is an observational, non-significant risk study to assess the progression of atrial fibrillation in subjects who received ablation treatment with either the FARAPULSE Pulsed Field Ablation System or thermal ablation in the ADVENT Trial.

    San Francisco, California and other locations

  • Health eHeart BEAT-AFib - Health eHeart Biomarkers of Early Atrial Transformation in Atrial Fibrillation

    Sorry, accepting new patients by invitation only

    Atrial fibrillation (also known as AFib or AF) is the most common abnormal heart rhythm and results in an irregular beating of the heart. Currently, there is no way of identifying patients at most risk for the development or progression of AFib or those that will best respond to treatment. The purpose of this study is to improve our understanding of AFib and to find new ways of identifying those patients most at risk for developing AFib, have progressive AFib or be less responsive to treatment. For this reason, the investigators are studying imaging, blood, and digital markers that may contribute to AFib Subjects will receive mobile devices (uch as an AliveCor Kardia and a VivaLnk Wearable ECG patch or similar devices) for remote electrocardiographic (ECG) monitoring. Additionally, subjects will use features using a smartphone research app (on the Eureka Research Platform) to monitor other important things such as activity, sleep, heart rate and others as they are developed. All subjects will receive serial blood draws and saliva sample collections once a year. Subjects will also undergo annual imaging in the form of an echocardiogram (Echo). Evaluations will be taken at baseline and once a year for three years from the baseline visit. Additionally, electronic surveys will be administered periodically (eVisits occurring every 3-6 months) using the mobile app.

    San Francisco, California

Our lead scientists for Atrial Fibrillation research studies include .

Last updated: